FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67707
Video■ Mixed
Johnson & Johnson CEO on Why He’s Not Focusing on GLP-1s
KINDVideo
DIRECTION■ Mixed
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 17:13 UTC
LAST UPDATE2026-10-06 17:13 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
J&J skipping GLP-1 obesity boom to focus oncology and dementia; differentiates strategy from Lilly's obesity leadership.
J&J bets against obesity race, on oncology
CATALYST TO WATCH
Pipeline data in cancer and dementia
MAIN RISK
Missing the largest pharma growth market
FULL DISPATCH
Johnson & Johnson CEO Joaquin Duato explains why the healthcare giant is skipping the obesity drug boom to focus on curing cancer and addressing dementia. He sat down with David M Rubenstein. For more, watch Peer to Peer Conversations #health #glp1
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare, LLY
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
→CORRELATIONshares JNJ, Healthcare
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
→CORRELATIONshares Healthcare
Biobeat Brings Leading Hypertension Voices to AHA Hypertension Scientific Sessions as Conversation Shifts to Cuffless 24-Hour Ambulatory Blood Pressure Monitoring2026-10-06 17:24 UTC
Biobeat Brings Leading Hypertension Voices to AHA Hypertension Scientific Sessions as Conversation Shifts to Cuffless 24-Hour Ambulatory Blood Pressure Monitoring2026-10-06 17:24 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.